GlassScriptPhysician profile
Taylor Harrison Polk
NPI 1093343584
$1,842.96
in general payments reported to CMS, 2019-2025
24 companies · $884 in 2025
The $884 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $795 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $166.91 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $161.31 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $134.77 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $133.66 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $95.16 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $91.93 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $82.43 | 2023-2024 | |
| Ardelyx, INC. | $75.18 | 2024-2025 | Ibsrela |
| Amgen INC. | $74.16 | 2024 | Tepezza |
| Corcept Therapeutics | $63.52 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.41 | 2025 | Xifaxan |
| Abbott Laboratories | $38.31 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $36.06 | 2024-2025 | |
| Antares Pharma, INC. | $33.67 | 2024-2025 | Xyosted |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.70 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Intercept Pharmaceuticals, INC. | $24.35 | 2025 | |
| Bridgebio Pharma, INC. | $23.07 | 2025 | Attruby |
| Horizon Therapeutics Plc | $21.50 | 2023 | Tepezza |
| Phathom Pharmaceuticals, INC. | $17.71 | 2025 | Voquezna |
| Radius Health, INC. | $17.00 | 2024 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Exact Sciences Corporation | $14.41 | 2024 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.00 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.